Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Litfulo on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Litfulo (ritlecitinib) is an oral JAK/TEC inhibitor approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
Litfulo works by inhibiting Janus kinase 3 (JAK3) and TEC family kinases, which play a role in the immune-mediated attack on hair follicles that causes alopecia areata. By modulating this immune activity, Litfulo helps enable hair regrowth in eligible patients.
Litfulo is indicated for patients 12 years and older with severe alopecia areata, a condition marked by significant patchy or complete hair loss.
The recommended dose of Litfulo is 50 mg taken orally once daily, with or without food.
Boxed Warning — Litfulo: Litfulo carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. Patients treated with JAK inhibitors are at increased risk of serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis, that may lead to hospitalization or death. A higher rate of all-cause mortality, including sudden cardiovascular death, has been observed with another JAK inhibitor compared to TNF blockers. Malignancies, including lymphoma, have occurred, along with a higher rate of MACE and thrombosis (deep vein thrombosis, pulmonary embolism, and arterial thrombosis).
Patients should be evaluated for tuberculosis before starting treatment and monitored for signs of infection throughout therapy. Litfulo should be avoided in patients with active serious infections.
Hematologic parameters, including absolute lymphocyte count and platelet count, should be monitored before and during treatment.
Patients, particularly current or past smokers and those with other cardiovascular risk factors, should be evaluated for malignancy and cardiovascular risk before and during treatment.
Litfulo may cause fetal harm. Effective contraception should be used during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Litfulo is manufactured and marketed by Pfizer. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating dermatologist confirming the diagnosis of severe alopecia areata. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for severe alopecia areata, Litfulo is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Litfulo directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Litfulo should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Litfulo through NPP's regulated import pathway, with dermatology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support dermatology care coordination and documentation for Litfulo access.
Delhi's major hospitals assist patients with prescription support and documentation for Litfulo.
Bangalore's specialist network offers access coordination for eligible patients seeking Litfulo.
Chennai-based dermatology specialists coordinate Litfulo access alongside comprehensive alopecia care.
Hyderabad's care institutions support patients pursuing Litfulo therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Litfulo.
Pune-based specialists assist with prescription support and Litfulo treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Litfulo.
Kochi's specialist units assist patients with the documentation needed for Litfulo access.
Chandigarh's care centers support Litfulo treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Litfulo access process.
Lucknow-based centers assist patients pursuing Litfulo therapy.
Bhubaneswar's institutions support access to Litfulo for eligible patients.
Guwahati's specialists help coordinate Litfulo access for patients across the Northeast.
Patients in other cities across India can also access Litfulo through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
